Trials / Withdrawn
WithdrawnNCT02980263
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 28 Days – 10 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to evaluate whether, in Intravenous Immunoglobulin-naïve or refractory patients diagnosed with active Kawasaki disease, administration of canakinumab controls fever and acute phase reactants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canakinumab |
Timeline
- Start date
- 2016-11-15
- Primary completion
- 2017-11-30
- Completion
- 2017-11-30
- First posted
- 2016-12-02
- Last updated
- 2017-02-17
Source: ClinicalTrials.gov record NCT02980263. Inclusion in this directory is not an endorsement.